ID: ALA3409337

Max Phase: Preclinical

Molecular Formula: C22H27N5O6S

Molecular Weight: 489.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc2[nH]cc(CCCCCCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)c2c(=O)[nH]1

Standard InChI:  InChI=1S/C22H27N5O6S/c23-22-26-18-17(20(31)27-22)12(11-24-18)5-3-1-2-4-6-13-7-9-15(34-13)19(30)25-14(21(32)33)8-10-16(28)29/h7,9,11,14H,1-6,8,10H2,(H,25,30)(H,28,29)(H,32,33)(H4,23,24,26,27,31)/t14-/m0/s1

Standard InChI Key:  BSXZWPIJIYKAQE-AWEZNQCLSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 489.55

Molecular Weight (Monoisotopic): 489.1682

AlogP: 2.29

#Rotatable Bonds: 13

Polar Surface Area: 191.26

Molecular Species: ACID

HBA: 7

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.63

CX Basic pKa: 4.86

CX LogP: 1.82

CX LogD: -3.26

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.20

Np Likeness Score: -0.27

References

1. Wang Y, Mitchell-Ryan S, Raghavan S, George C, Orr S, Hou Z, Matherly LH, Gangjee A..  (2015)  Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.,  58  (3): [PMID:25602637] [10.1021/jm501787c]

Source

Source(1):

• Scientific Literature